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Background: This study characterized a cohort of chronic obstructive pulmonary disease 
(COPD) patients on maintenance bronchodilator monotherapy for $6 months to establish their 
disease burden, measured by health care utilization.
Methods: Data were extracted from the UK Clinical Practice Research Datalink and linked to 
Hospital Episode Statistics. The monotherapy period spanned the first prescription of a long-
acting β
2
-adrenergic agonist or a long-acting muscarinic antagonist until the end of the study 
(December 31, 2013) or until step up to dual/triple therapy, for example, addition of another 
long-acting bronchodilator, an inhaled corticosteroid, or both. A minimum of four consecutive 
prescriptions and 6 months on continuous monotherapy were required. Patients ,50 years 
old at first COPD diagnosis or with another significant respiratory disease before starting 
monotherapy were excluded. Disease burden was evaluated by measuring patients’ rate of 
face-to-face interactions with a health care professional (HCP), COPD-related exacerbations, 
hospitalizations, and referrals.
Results: A cohort of 8,811 COPD patients (95% Global initiative for chronic Obstructive 
Lung Disease stage A/B) on maintenance monotherapy was identified between 2002 and 2013; 
45% of these patients were still on monotherapy by the end of the study. Median time from 
first COPD diagnosis to first monotherapy prescription was 56 days, while the median time 
on maintenance bronchodilator monotherapy was 2 years. The median number of prescrip-
tions was 14. On average, patients had 15 HCP interactions per year, and one in ten patients 
experienced a COPD exacerbation (N=8,811). One in 50 patients were hospitalized for COPD 
per year (n=4,848).
Conclusion: The average monotherapy-treated patient had a higher than average HCP inter-
action rate. We also identified a large cohort of patients who were stepped up to triple therapy 
despite a low rate of exacerbations. The use of the new class of long-acting muscarinic antagonist/
long-acting β
2
-adrenergic agonist fixed-dose combinations may provide a useful step-up treat-
ment option in such monotherapy patients, before the use of inhaled corticosteroids.
Keywords: COPD, UK primary care setting, bronchodilators, prescribing patterns, monotherapy
Background
Chronic obstructive pulmonary disease (COPD) is an umbrella term used to 
describe chronic lung diseases that cause limitations in lung airflow, usually due 
to cigarette smoking.1 COPD is characterized by airflow obstruction that is usually 
progressive, partially reversible, and does not change markedly over several months.2 
The most common symptoms of COPD are breathlessness, excessive sputum produc-
tion, and chronic cough. Patients can also experience acute exacerbations usually 
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associated with viral respiratory infections, which are a 
hallmark of COPD, further impairing the quality of life and 
health status.3 COPD is a highly prevalent and debilitating 
disease that has a significant impact on the costs borne by 
the health care system. According to the latest World Health 
Organization estimates, more than three million people died 
of COPD in 2012, which is equal to 6% of all deaths global-
ly.3 The prevalence of COPD is difficult to estimate due to 
different definitions of COPD and underdiagnosis. In the UK, 
~900,000 people have been diagnosed with COPD, while it 
is estimated that another two million people have COPD that 
remains undiagnosed.4
Inhaled bronchodilator medications such as long-acting 
β
2
-adrenergic agonists (LABA) or long-acting muscarinic 
antagonists (LAMA) are the cornerstones of symptomatic 
COPD treatment. Inhaled corticosteroids (ICS) are also 
widely used in COPD management primarily to reduce the 
risk of exacerbations, especially in patients with an eosino-
philic component.5 ICS are only licensed in combination with 
a LABA in the treatment of COPD. Their role in COPD is 
controversial, as the use of ICS is associated with a number 
of local and systemic side effects such as oral candidiasis, 
increased risk of pneumonia,6 and osteoporosis. This is 
reflected in treatment guidelines where the use of ICS is nor-
mally reserved as a second- or third-line maintenance treat-
ment option.7 However, there is evidence to suggest that in 
the primary care setting in the UK, prescribers are not always 
following these guidelines, resulting in a substantial propor-
tion of patients being inappropriately prescribed ICS.
The National Institute for Health and Care Excellence 
(NICE) 2010 COPD guidelines recommend short-acting 
bronchodilators as reliever medication,2 and when these 
agents have failed to control symptoms, a long-acting 
maintenance bronchodilator (LABA or LAMA) is indicated. 
The NICE guidelines reserve the use of ICS as a first-line 
treatment for patients with forced expiratory volume in 
1 second (FEV
1
) ,50% or having exacerbations, or for those 
with symptoms not controlled on monotherapy. The Global 
initiative for chronic Obstructive Lung Disease (GOLD) 
2016 strategy recommends the use of ICS only for patients 
with severe or very severe airflow limitation and/or two or 
more exacerbations per year or any exacerbation leading 
to hospitalization.7
Further deterioration of lung function usually requires 
the progressive introduction of more treatments, both phar-
macologic and nonpharmacologic, attempting to limit the 
impact of these changes. As the disease progresses, patients 
with COPD may be stepped up to dual and triple therapy 
pharmacologic treatment regimens.
This retrospective study aimed to establish the burden of 
disease for COPD patients treated with maintenance broncho-
dilator monotherapy (either a LABA or LAMA) in the UK. 
To do so, we evaluated how many resources these patients 
used (ie, visits to a general practitioner [GP] and referrals to 
specialist care) and how many health issues they encountered 
(COPD exacerbations and hospitalizations) over the course of 
their monotherapy treatment period until these patients were 
stepped up to dual or triple therapy. As a marker of unmet 
need, we also studied the time taken to step up to dual/triple 
therapy for different monotherapy patient subgroups.
Patients and methods
study population
This was a retrospective cohort study of COPD patients 
identified from primary care setting in the UK using the 
Clinical Practice Research Datalink (CPRD). The CPRD 
is a database of longitudinal patient primary care records, 
containing anonymized data of patient demographics, diag-
noses, referrals, prescriptions, and health outcomes from 
over 660 GP practices in the UK. Validation studies have 
confirmed the high quality of the data and completeness of 
clinical records within the CPRD.8–12
Data from patients first diagnosed with COPD between 
January 2002 and December 2011 who were $50 years old 
at diagnosis were extracted from the CPRD. All patients with 
another significant respiratory disease (eg, asthma, bron-
chiectasis, lung cancer/carcinoma, cystic fibrosis, interstitial 
lung disease, and pulmonary thromboembolic disease) or a 
history of lung transplant prior to the start of monotherapy 
were excluded. In order to minimize the likelihood of includ-
ing asthmatics or patients with both asthma and COPD diag-
noses, the sample was restricted to patients aged $50 years 
at the time of COPD diagnosis.
exposures
Patients had to be on either a LABA or a LAMA as mono-
therapy for at least 180 days. In addition, patients had to have 
at least 6 months of continuous CPRD records following the 
end of their specific period on monotherapy, that is, valid 
records, and be alive and enrolled in the practice during this 
period. The use of short-acting β
2
-adrenergic agonist (SABA) 
or short-acting muscarinic antagonist therapies did not affect 
inclusion into the study.
Time on maintenance monotherapy was defined from 
the first prescription of a LABA or a LAMA until the end 
of the study period (December 31, 2013) or until step up to 
dual/triple therapy, for example, addition of another long-
acting bronchodilator, an ICS, or ICS/LABA. A minimum of 
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four consecutive prescriptions and 6 months on continuous 
monotherapy were required for study entry.
Outcomes
The following disease outcomes were investigated during the 
monotherapy period and during the 6 months following the 
end of monotherapy:
•	 number of GP visits;
•	 number of exacerbations defined: 1) as addition of 
antibiotics and/or oral corticosteroids (within 5 days of 
initiation of antibiotics) to the patient’s medication and 2) 
by CPRD medical codes;
•	 number of (inpatient) hospitalizations linking to Inte-
grated Hospital Episode Statistics (HES) data;
•	 number of referrals, defined as consultations to the 
appropriate clinical specialties (respiratory medicine, 
geriatrics, general medicine, and accident and emergency) 
for COPD-related reasons.
To identify the hospitalizations due to COPD exacerba-
tions (International Statistical Classification of Diseases 
and Related Health Problems tenth revision code: J44.1), 
we used the integrated HES dataset. Only for this outcome, 
we restricted the cohort to those patients in CPRD with a 
linked HES record.
Covariates
The population demographics identified and described in this 
study included age, sex, FEV
1
, body mass index, and smoking 
history. We also investigated the presence of concomitant 
comorbidities at the time of COPD diagnosis, including 
acute myocardial infarction, congestive heart disease, atrial 
fibrillation, renal impairment (chronic kidney disease stages 3 
through 5), cerebrovascular disease, cancer, diabetes, and 
peripheral vascular disease.
Within the maintenance monotherapy cohort, patients 
were stratified by severity categories (A, B, C, or D) as 
defined by the GOLD stages of airflow obstruction.13 
Severity was determined by combining data from response 
to the Medical Research Council dyspnea questionnaire, by 
the number of exacerbations in the past 12 months, and by 
FEV
1
 (as % of predicted). In the absence of spirometry and/or 
dyspnea score, the patients’ COPD exacerbation history 
was considered, and all patients were categorized as having 
either #2 or .2 exacerbations within the past year and were 
categorized as A/B or C/D, respectively.
Data analysis
Descriptive statistics were used for the baseline character-
istics of the cohort of patients first diagnosed with COPD 
between 2002 and 2011, as well as for the rate of the four 
outcomes of interest.
Survival analysis was used for descriptive purposes 
to calculate the 1-year step-up rate (from monotherapy 
to dual or triple therapy), and a Cox proportional hazards 
model was used to compare the time to step up in patient 
subgroups (eg, male vs female patients, patients aged 50–70 
vs .70 years, and GOLD severity A/B vs C/D). Patients who 
stayed on monotherapy or died or were transferred out of 
practice before December 31, 2013 were censored.
ethics
The study was conducted in accordance with the principles 
outlined in the Declaration of Helsinki. The CPRD group 
has obtained ethical approval from a National Research 
Ethics Service Committee and is recognized and validated 
by the health research authority (http://www.hra.nhs.uk/
about-the-hra/our-committees/research-ethics-committees-
recs/) for all purely observational research using anonymized 
CPRD data, namely, those studies which do not include 
patient involvement (which form the vast majority of CPRD 
studies). An Independent Scientific Advisory Committee 
(ISAC) is responsible for reviewing the protocols for scien-
tific quality, but may recommend that study-specific ethical 
approval is sought if ethical issues arise in relation to an 
individual study. The present study was approved by the 
CPRD ISAC (protocol 14_102A). Patient consent was not 
required by the National Research Ethics Service Committee 
for this CPRD study due to anonymity of the data.
Results
Patients
By the end of 2013, there were ~3.7 million active patients 
within the CPRD, which is a representative sample of the 
total UK population (of ~60 million). We extracted the GP 
records of 82,652 COPD patients who were $50 years of 
age at the time of their first COPD diagnosis, of whom 70% 
(n=57,882) had at least one LABA code or one LAMA code 
at any time in their medical history (Figure 1).
Of these 57,882 patients, 13,382 (23%) were prescribed 
a LAMA as their first prescription and had no other con-
comitant prescriptions; 70% (n=9,346) of these were on a 
LAMA for a continuous period of 180 days or more. After 
excluding the patients who may not have received $4 
prescriptions during that 180-day (or longer) time period, 
8,029 LAMA monotherapy patients remained. Finally, on 
including only those patients who remained alive and had 
valid CPRD records for 6 months following the end of their 
monotherapy period, 6,969 LAMA patients remained. The 
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same process was applied for LABA monotherapy, which 
led to 1,842 patients remaining.
Thus, a cohort of 8,811 patients with COPD (95% GOLD 
stage A or B) on maintenance monotherapy was identified. 
Basic demographics of this cohort, stratified by COPD 
severity, are presented in Table 1. The majority of patients 
were male (56%) and current smokers (63%). A high propor-
tion of patients (5%–10%) had another comorbid disease at 
diagnosis of COPD, including acute myocardial infarction, 
history of cerebrovascular disease, congestive heart disease, 
atrial fibrillation, renal impairment, cancer, diabetes, and 
peripheral vascular disease (Table 1).
Treatments
Among the cohort of 8,811 patients with COPD (95% GOLD 
stage A or B) on maintenance monotherapy, 45% (n=3,947) 
were still on monotherapy at the last record or by the end of 
the study period. Of these, 3,297 (84%) were only ever on a 
LAMA, 49 (1%) were on a LAMA and switched to a LABA, 
546 (14%) were only ever on a LABA, and 55 (1%) were on 
a LABA and switched to a LAMA.
For all patients, the median time on maintenance bron-
chodilator monotherapy was 2 years and the median time 
from first COPD diagnosis to first monotherapy prescription 
was 56 days. The median number of prescriptions during 
this period was 14, corresponding to the mean prescrip-
tion duration of 53.4 days. The yearly rate of short-acting 
bronchodilator prescriptions during monotherapy was 3.9 
(interquartile range, 7.1; N=8,811), most of which were 
SABA prescriptions.
Among the 55% of COPD patients (n=4,864) who stepped 
up to dual or triple therapy, the treatments added on were as 
follows: in 11% was added the other class of monotherapy 
(LABA or LAMA), in 9% was added an ICS, and in 34% was 
added an ICS + LABA. Figure 2 identifies the proportion of 
patients on different combinations of COPD medications at 
the end of the study, while the length of time on monotherapy 
by the type of treatment received at the end of the study is 
shown in Figure 3.
Outcomes
Patients had an average of 15 health care professional (HCP) 
consultations per year; one in ten patients experienced a 
COPD exacerbation (mean: 0.1; 95% confidence interval 
[CI]: 0.1, 0.2; N=8,811) and one in 50 patients were hospi-
talized for COPD per year (mean: 0.02; 95% CI: 0.01, 0.02; 
n=4,848) (Table 2).
While the frequency of use of short-acting bronchodila-
tors, measured as the total number of prescriptions collected 
over the years, increases with the time spent on monotherapy, 
as expected, the yearly rate of short-acting bronchodilator 
use (scripts/year) decreased with increasing time spent on 
monotherapy. In stratified analyses by years spent on mono-
therapy, we found that patients who remain on monotherapy 
(45%) use less short-acting medication than those who step 
up to dual/triple therapy at every time point (Figure 4).
In adjusted models, higher COPD severity (hazard ratio 
[HR] =1.33; 95% CI: 1.17, 1.52), higher rate of yearly short-
acting medication usage (HR =1.05; 95% CI: 1.05, 1.06), and 
history of peripheral vascular disease (HR =1.15; 95% CI: 
1.02, 1.29) all predict a statistically significant higher hazard 
of stepping up to dual/triple therapy. Conversely, history of 
diabetes (HR =0.78; 95% CI: 0.70, 0.87), rate of aspirin usage 
during monotherapy (HR =0.99; 95% CI: 0.98, 0.99), and 
female sex (HR =0.94; 95% CI: 0.89, 1.00) predict a lower 
hazard of stepping up.
+DGDWOHDVWRQH/$%$RURQH/$0$DWDQ\WLPHLQPHGLFDOKLVWRU\
\HDUROG&35'SDWLHQWVZLWKDILUVW&23'GLDJQRVLVGXULQJ±
/$%$RU/$0$ZDVWKHILUVWS[
1RRWKHUFRQFRPLWDQWS[RQWKDWILUVWS[GDWH
2QPRQRWKHUDS\IRUGD\V
0LQLPXPIRXU/$%$RU/$0$S[V
3UDFWLFHH[FOXVLRQVDSSOLHG
1RRWKHUUHVSLUDWRU\FRQGLWLRQVSULRUWRILUVWPRQRWKHUDS\S[
Figure 1 Flowchart for sample selection.
Abbreviations: COPD, chronic obstructive pulmonary disease; CPrD, Clinical 
Practice research Database; laBa, long-acting β2-adrenergic agonist; laMa, long-
acting muscarinic antagonist; px, prescription.
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Discussion
In this study population, we found that the median time 
from initial COPD diagnosis to initiation of maintenance 
monotherapy treatment was 56 days. The median time 
patients spent on maintenance monotherapy before being 
stepped up to dual/triple therapies was 2.1 years. During 
their time on maintenance monotherapy, patients demon-
strated low rates of COPD exacerbations, specialist refer-
rals, and hospitalizations. This is perhaps unsurprising, 
considering that due to the inclusion criteria of the study 
Table 1 Patient demographics
Characteristics All COPD patients (%) 
(N=8,811)
By GOLD severity
Severity A/B (%) 
(n=8,371; 95% of 
all patients)
Severity C/D (%) 
(n=440; 5% of  
all patients)
P-value
Male 4,950 (56) 4,688 (56) 262 (60) 0.1443
Female 3,861 (44) 3,683 (44) 178 (40)
smoking historya
Current smoker 5,577 (63) 5,257 (63) 320 (73)
ex-smoker 1,220 (14) 1,166 (14) 54 (12)
nonsmoker 2,010 (23) 1,944 (23) 66 (15) 0.0002
Comorbidities at diagnosis
acute myocardial infarction 726 (8) 702 (8) 24 (5) 0.029
Congestive heart disease 490 (6) 469 (6) 21 (5) 0.459
Atrial fibrillation 607 (7) 585 (7) 22 (5) 0.109
renal impairmentb 798 (9) 763 (9) 35 (8) 0.409
Cerebrovascular disease 511 (6) 496 (6) 15 (3) 0.028
Cancer 655 (7) 624 (7) 31 (7) 0.750
Diabetes 778 (9) 737 (9) 41 (9) 0.711
Peripheral vascular disease 589 (7) 566 (7) 23 (5) 0.209
Duration of monotherapy, years
0.5–#1 1,570 (18) 1,447 (17) 123 (28) ,0.001
.1–2 2,693 (31) 2,535 (30) 158 (36)
.2–3 1,934 (22) 1,851 (22) 83 (19)
.3–4 1,149 (13) 1,098 (13) 51 (12)
.4–5 594 (7) 576 (7) 18 (4)
.5 871 (10) 864 (10) 7 (2)
rate of use of short-acting medication (prescriptions per year)
Tertile 1 (#1.9) 2,906 (33) 2,808 (34) 98 (22) ,0.001
Tertile 2 (.1.9–6.5) 2,997 (34) 2,850 (34) 147 (33)
Tertile 3 (.6.5) 2,908 (33) 2,713 (32) 195 (44)
Notes: aat the closest time prior to diagnosis date (n=8 unspecified). bChronic kidney disease stages 3–5. results are based on Chi-squared test (P,0.05). 
Abbreviations: COPD, chronic obstructive pulmonary disease; gOlD, global initiative for chronic Obstructive lung Disease.
$GGVRWKHUPRQRWKHUDS\FODVV











3UR
SRU
WLRQ
RIS
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
$GGV,&6 $GGV,&6/$%$ 6WD\VRQPRQRWKHUDS\
/$0$Q /$%$Q $OOSDWLHQWV1 
Figure 2 Medication switches in patients initially prescribed laMa or laBa 
monotherapy.
Abbreviations: ICs, inhaled corticosteroid; laBa, long-acting β2-adrenergic 
agonist; laMa, long-acting muscarinic antagonist.
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Figure 3 Time on monotherapy by the type of therapy received at the end of the study.
Note: Thirteen patients were stepped up to a laBa + LAMA fixed-dose combination.
Abbreviations: ICs, inhaled corticosteroid; laBa, long-acting β2-adrenergic 
agonist; laMa, long-acting muscarinic antagonist.
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requiring patients to have been stable on monotherapy for 
a minimum of 6 months, majority of the study popula-
tion (95%) were observed to be mild to moderate GOLD 
stage A+B patients. COPD patients with accelerated or 
more severe baseline disease would likely have been 
stepped up to more advanced treatment sooner and were 
less likely to have met the 6-month monotherapy inclu-
sion criteria.
Conversely, it was noted that HCP interaction rates were 
relatively high among the monotherapy population at a mean 
of 15 consultations per year; though we have no comparison 
group in the present study, the national average GP consulta-
tion rate per patient is 5.5 per year.14 It should be noted that 
it was not possible to determine if these HCP interactions 
were primarily COPD related. We also noted that presence 
of diabetes was associated with longer use of monotherapy 
in adjusted Cox proportional hazard models, and possible 
explanations could include prescribers’ concerns over the 
effects of ICS on glycemic status.15 Aspirin use was also 
associated with a longer maintenance period on monotherapy. 
While we have no direct explanation for these observations, 
we could hypothesize that managing other comorbidities may 
detract from COPD management.
This study identified a cohort of COPD patients who 
were maintained on LABA or LAMA maintenance mono-
therapy. Overall, 45% of the study population remained on 
monotherapy throughout the study period and 30% had been 
on monotherapy maintenance treatment for over 3 years. The 
population that remained on monotherapy throughout the 
study was found to have a lower frequency of short-acting 
bronchodilator use than the patient population that stepped 
up treatment during the trial period across all time points. 
This could reflect better symptom control and/or lower 
severity of disease.
Interestingly, we observed that there was a decrease in 
the yearly rate of SABA use the longer the patients remained 
on monotherapy. This trend was observed in both the mono-
therapy and step-up treatment groups; however, the patients 
who remained on monotherapy at the end of the study dem-
onstrated a lower rate of yearly SABA use compared to those 
who were stepped up in treatment across all time points. This 
could be due to various factors, such as patients having greater 
Table 2 rate of outcomes
Rate of outcomes All COPD patients 
(N=8,811) mean rate 
(95% CI)
By GOLD severity
Severity A/B (n=8,371) 
mean rate (95% CI)
Severity C/D (n=440) 
mean rate (95% CI)
P-value
rate of hCP interactions per yeara 14.8 (14.7, 15.1) 14.8 (14.6, 15.0) 14.6 (13.7, 15.4) 0.584
rate of COPD exacerbations per year
Using read codes for “COPD exacerbation” 0.1 (0.1, 0.2) 0.1 (0.1, 0.1) 0.3 (0.3, 0.4) ,0.001
By addition of oral steroids and/or antibiotics to 
the patient’s regimeb
1.1 (1.0, 1.1) 1.1 (1.0, 1.1) 1.2 (1.1, 1.4) 0.024
rate of referrals per year 0.7 (0.7, 0.8) 0.7 (0.7, 0.8) 0.6 (0.5, 0.6) 0.005
rate of COPD hospitalizations (inpatient) per yearc 0.02 (0.01, 0.02)
(n=4,848)
0.02 (0.01, 0.02)
(n=4,591)
0.01 (0.00, 0.03)
(n=257)
0.779
Notes: aIncluding only face-to-face or hCP interactions and excluding .1 consultation event on the same day. bFirst-line antibiotics prescription or a combination of second-
line antibiotics and oral corticosteroid prescriptions (within 15 days). camong n=4,848 (55% of 8,811) who linked up to hospital statistics. results are based on ordered 
logistic regression (P,0.05).
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; GOLD, Global initiative for chronic Obstructive Lung Disease; HCP, health care 
professional.
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Figure 4 Frequency and rate of short-acting bronchodilator usage by monotherapy duration.
Note: Frequency (A) and rate (B) of short-acting bronchodilator usage by monotherapy duration.
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confidence in using their long-acting maintenance treatment 
or managing their disease over time, or conversely, it could 
represent worsening noncompliance for SABA use.
The 2010 NICE COPD treatment guidelines are based on 
patient airflow limitation and exacerbation history; however, 
they also allow patients to be stepped up to an ICS/LABA 
combination when they are deemed to be still symptomatic 
despite the recommended treatment, even if they have no 
history of exacerbations and/or mild airflow limitation.2 The 
current 2016 GOLD guidelines recommend the use of ICS/
LABA combinations only in GOLD stage C+D patients based 
on exacerbation history and/or airflow limitation parameters.7 
If the GOLD treatment criteria are applied to the primary care 
setting in the UK, it is recognized that a high proportion of 
GOLD stage A+B patients may have been inappropriately 
prescribed an ICS/LABA for maintenance treatment, which 
can increase their risk to ICS-associated adverse effects.7 
In our study, it was observed that within 2 years of initiat-
ing treatment for COPD, ICS therapy was added to 43% of 
patients on LABA or LAMA monotherapy, despite the low 
rate of exacerbations. This may reflect inappropriate initia-
tion of ICS as previously described and is in line with the 
findings from other studies.16,17
As with all studies using retrospective health information 
data, our study had some limitations. A record of a prescrip-
tion in CPRD does not capture whether the script was dis-
pensed or the medicine was taken by the patient, suggesting 
that this study was based on prescribing behavior. Other 
limitations include the scarcity of pulmonary function data, 
which can contribute to overdiagnosis, and the absence of 
health status data. In addition, any treatments administered 
outside of the primary care setting were not included in this 
study. The analysis used to determine the rate of hospital-
izations required patients to have a linked HES record, and 
thus, the sample size for this analysis was limited to 55% of 
the total patients. Last, though this study evaluated data from 
patients first diagnosed with COPD between January 2002 
and December 2011, treatment was assessed according to 
current COPD guidelines in order to maintain the relevance 
of the data to current practice.
Conclusion
From this study, we identified that the average monotherapy-
treated patient required 15 HCP interactions per year. We also 
found that a large number of patients were stepped up to 
ICS treatment despite having no increase in exacerbations. 
The use of the new class of LAMA/LABA fixed-dose com-
binations may be a useful clinical step-up option in such 
monotherapy patients, prior to the use of ICS.
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